The role of ifosfamide and cyclophosphamide in the multi-modality treatment after surgery for cure for small-cell bronchial carcinomas (SCLC)
| Autor: | A. Lattuneddu, K. Karrer, J. Rothmund, E. Hata, H. Osada, G. M. Salzer, B. Berkarda, M. Thermann, M. L. Liao, Denck H, H. Karnicka-Mlodkowska, P. Drings, Orel J, Frank Bruno, Y. Sun |
|---|---|
| Rok vydání: | 1989 |
| Předmět: |
Cancer Research
medicine.medical_specialty medicine.medical_treatment Random Allocation Antineoplastic Combined Chemotherapy Protocols medicine Humans Multicenter Studies as Topic Ifosfamide Carcinoma Small Cell Cyclophosphamide Survival rate Postoperative Care Chemotherapy business.industry Bronchial Neoplasms Micrometastasis Lomustine medicine.disease Combined Modality Therapy Primary tumor Surgery Radiation therapy Oncology Prophylactic cranial irradiation business Follow-Up Studies medicine.drug |
| Zdroj: | Medical Oncology and Tumor Pharmacotherapy. 6 |
| ISSN: | 0736-0118 |
| DOI: | 10.1007/bf02985237 |
| Popis: | For the optimisation of the therapy for small cell bronchial carcinomas (SCLC), surgery is used to eliminate the primary tumor and its regional lymph nodes and chemo- and radiotherapy for the general treatment of micrometastasis. After patho-histological examination of the operation specimen, randomization for two arms is performed for a standard chemotherapy (CAV) or a sequential chemotherapy using three different drug combinations. Thereafter all disease-free patients receive prophylactic cranial irradiation (PCI). Preliminary evaluations in December 1987, of 112 patients from 19 cooperating departments show that the survival rate projected for 2 yr of 43 patients at stage pT1-3 N0 M0 is 76%, of 43 patients at stage pT1-3 N1 M0 it is 63% and of 26 patients at stage pT1-3 N2 M0 it is 38%. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|